Physician profile
Imran Zaffer
NPI 1437195427
$9,606.96
in general payments reported to CMS, 2019-2025
34 companies · $1,768 in 2025
The $1,768 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $630 · 2021: $1,197 · 2022: $1,467 · 2023: $1,516 · 2024: $1,597 · 2025: $1,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,872 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,871.71 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,306.08 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,153.36 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $710.19 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $698.72 | 2019-2025 | Entyvio, Eohilia |
| Ferring Pharmaceuticals INC. | $499.07 | 2019-2023 | Rebyota |
| Redhill Biopharma INC. | $427.52 | 2020-2025 | Talicia, Movantik, Aemcolo |
| Pfizer INC. | $402.13 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $391.01 | 2019-2025 | Ocaliva |
| Qol Medical, LLC | $335.86 | 2023-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $311.29 | 2021-2023 | |
| Daiichi Sankyo INC. | $288.40 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $277.56 | 2019-2023 | Dificid |
| Lilly USA, LLC | $256.14 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $211.87 | 2019-2024 | Suflave |
| Ironwood Pharmaceuticals, INC | $164.42 | 2019-2023 | Linzess |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $158.99 | 2023-2025 | Dupixent |
| Vivus LLC | $156.65 | 2024-2025 | Qsymia, Pancreaze |
| Celgene Corporation | $143.54 | 2021-2024 | Zeposia |
| Genzyme Corporation | $97.63 | 2023-2025 | |
| Ardelyx, INC. | $88.31 | 2023-2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $85.55 | 2023-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $73.27 | 2024-2025 | Zenpep |
| Concordia Pharmaceuticals INC. | $56.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.99 | 2023 | Cyltezo |
| Intra-Sana Laboratories | $43.64 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Allergan, INC. | $39.45 | 2019 | |
| Exact Sciences Corporation | $31.73 | 2025 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $30.00 | 2025 | Suflave |
| Qiagen, LLC | $29.56 | 2020-2021 | |
| Medtronic, INC. | $29.40 | 2024 | Gi Genius |
| Capsovision, INC. | $19.82 | 2024 | Capsocam Plus |
| Ipsen Biopharmaceuticals, INC | $17.97 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $14.67 | 2024 | Lesionhunter |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Zaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.